The primary endpoint is dose response based on objective response rate as measured by M protein levels, with secondary endpoints including comparison of response rates between doses, progression-free survival, time to treatment failure and overall survival...secondary objectives include survival, progression-free survival and the proportion of patients alive at six months
OncoGenex Technologies Inc., of Vancouver, British Columbia, and Isis Pharmaceuticals Inc., of Carlsbad, Calif., said preliminary Phase II data show that metastatic hormone refractory prostate cancer (HRPC) patients receiving second-line treatment with OGX-011 plus docetaxel achieved improved survival, longer progression-free survival, and more frequent decreases in prostate-specific antigen levels than patients receiving OGX-011 plus mitoxantrone
Primary objectives of the study are to determine MTD and dose-limiting toxicities of TH-302, which is administered as a 30-minute intravenous infusion, while secondary objectives include establishing pharmacokinetics and assessing anti-tumor activity, as measured by objective response rate, duration of response, progression-free survival, overall survival and various safety parameters
Efficacy will be measured by progression-free survival, as well as overall survival...The primary endpoint of the study already had demonstrated that patients receiving Removab had a fourfold increased puncture-free survival over a therapy with puncture alone
The primary endpoint of the trial is progression-free survival with secondary endpoints including duration of response, overall survival and overall safety/tolerability
Data from the 80-patient trial also showed a statistically significant increase in time to treatment failure and a significantly longer period (+116 percent) of progression-free survival for patients receiving HyCAMP compared to Camptosar...EntreMed Inc., of Rockville, Md., started a Phase II combination study with Panzem NCD (2-methoxyestradiol) and Temador (temozolomide, Schering-Plough Corp.) in patients with recurrent glioblastoma multiforme to determine progression-free survival
Antigencs Inc., of New York, said follow-up data from its Phase III trial of therapeutic cancer vaccine Oncophage (vitespen) showed that, in a substantial subset of patients at intermediate risk for disease recurrence, the product demonstrated a clinically significant improvement in recurrence-free survival of about 45 percent
According to SWOG, the 198 patients enrolled in the trial, prior to the closure, are sufficient to provide data analysis and evaluate the primary endpoint of progression-free survival (PFS) in the two arms of the trial
In addition, the mean progression-free survival was 96 days for Vectibix-treated patients compared to 60 days...Its primary efficacy endpoint is overall survival, and overall response rates, progression-free survival and disease control also will be evaluated. (See BioWorld Today, Jan. 4, 2007
Data examined to date showed that patients on HyCAMP were able to receive more doses (a median of six cycles of therapy compared to two for irinotecan along), and median progression-free survival for HyCAMP patients was 5.2 months, compared to 2.4 months for the Irinotecan arm
The primary endpoint is progression-free survival from randomization until disease progression or death...The primary endpoint is progression-free survival rate after 16 weeks
The first designation is in the first-line treatment of metastatic colorectal cancer to improve progression-free survival and overall survival when added to Avastin-containing 5-fluorourocil (5-FU)-based chemotherapy regimens
The primary endpoint is dose response based on objective response rate as measured by M protein levels, with secondary endpoints including comparison of response rates between doses, progression-free survival, time to treatment failure and overall survival...secondary objectives include survival, progression-free survival and the proportion of patients alive at six months